CY2360B1 - Hiv protease inhibitor combination. - Google Patents

Hiv protease inhibitor combination.

Info

Publication number
CY2360B1
CY2360B1 CY0300040A CY0300040A CY2360B1 CY 2360 B1 CY2360 B1 CY 2360B1 CY 0300040 A CY0300040 A CY 0300040A CY 0300040 A CY0300040 A CY 0300040A CY 2360 B1 CY2360 B1 CY 2360B1
Authority
CY
Cyprus
Prior art keywords
hiv protease
hiv
protease inhibitor
combination
inhibitor combination
Prior art date
Application number
CY0300040A
Other languages
English (en)
Inventor
Paul J Deutsch
Emilio A Emini
Joseph P Vacca
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CY2360B1 publication Critical patent/CY2360B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY0300040A 1994-08-11 2003-05-07 Hiv protease inhibitor combination. CY2360B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28947494A 1994-08-11 1994-08-11
US33936994A 1994-11-14 1994-11-14
US49246195A 1995-07-20 1995-07-20

Publications (1)

Publication Number Publication Date
CY2360B1 true CY2360B1 (en) 2004-06-04

Family

ID=27403895

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0300040A CY2360B1 (en) 1994-08-11 2003-05-07 Hiv protease inhibitor combination.

Country Status (19)

Country Link
EP (1) EP0774969B8 (de)
JP (1) JPH10504036A (de)
KR (1) KR970704441A (de)
CN (1) CN1101190C (de)
AT (1) ATE232727T1 (de)
AU (1) AU698664B2 (de)
CA (1) CA2197207C (de)
CY (1) CY2360B1 (de)
CZ (1) CZ292577B6 (de)
DE (1) DE69529678T2 (de)
DK (1) DK0774969T3 (de)
ES (1) ES2190456T3 (de)
HU (1) HUT76540A (de)
IL (1) IL114808A (de)
MX (1) MX9701121A (de)
NO (1) NO314168B1 (de)
PL (1) PL181578B1 (de)
SK (1) SK18197A3 (de)
WO (1) WO1996004913A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2270546A1 (en) * 1996-11-08 1998-05-22 Japan Energy Corporation Aids remedy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US517041A (en) * 1894-03-27 Fruit-picker
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
CA2096408C (en) * 1990-11-19 2005-02-08 Gary Anthony Decrescenzo Retroviral protease inhibitors
DK0558657T3 (da) * 1990-11-19 1997-07-07 Monsanto Co Retrovirale proteaseinhibitorer
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
ATE163926T1 (de) * 1991-11-08 1998-03-15 Merck & Co Inc Hiv-protease-inhibitoren verwendbar in der aids- behandlung
EP1302468B1 (de) * 1992-12-29 2008-12-17 Abbott Laboratories Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern

Also Published As

Publication number Publication date
NO970632L (no) 1997-04-10
CA2197207A1 (en) 1996-02-22
SK18197A3 (en) 1997-09-10
ATE232727T1 (de) 2003-03-15
CA2197207C (en) 2006-10-17
NO970632D0 (no) 1997-02-11
DE69529678T2 (de) 2003-09-25
HUT76540A (en) 1997-09-29
EP0774969B1 (de) 2003-02-19
PL318506A1 (en) 1997-06-23
AU698664B2 (en) 1998-11-05
AU3361195A (en) 1996-03-07
IL114808A (en) 1999-10-28
CN1101190C (zh) 2003-02-12
CZ292577B6 (cs) 2003-10-15
JPH10504036A (ja) 1998-04-14
EP0774969B8 (de) 2003-07-02
MX9701121A (es) 1997-05-31
EP0774969A1 (de) 1997-05-28
DE69529678D1 (de) 2003-03-27
KR970704441A (ko) 1997-09-06
IL114808A0 (en) 1995-12-08
NO314168B1 (no) 2003-02-10
PL181578B1 (pl) 2001-08-31
CN1160350A (zh) 1997-09-24
ES2190456T3 (es) 2003-08-01
WO1996004913A1 (en) 1996-02-22
CZ38997A3 (en) 1997-11-12
DK0774969T3 (da) 2003-03-31

Similar Documents

Publication Publication Date Title
AU2725392A (en) Hiv protease inhibitors
MY109834A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
ATE252081T1 (de) Neue hiv-protease-inhibitoren
PL314984A1 (en) Hiv protease inhibitors
DZ1766A1 (fr) Inhibiteurs de vih protéase utiles pour le traitement du sida.
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
WO1996000068A3 (en) Combination therapy for hiv infection
EP0774969B8 (de) Kombinationen von hiv-protease inhibitoren
FI970565A0 (fi) HIV-proteaasia inhiboiva yhdistelmä
WO2002096359A3 (en) Piperazine pentanamide hiv protease inhibitors